Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Advanced Prostate Cancer

Expert Opinion / Cases · February 20, 2020

Widely Metastatic Prostate Cancer at Diagnosis

Written by
Jeffrey J. Tosoian MD, MPH

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Jeffrey Tosoian MD, MPH

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Comment deleted by Moderator.

  • Noureddine Benjaafar

    Feb 21, 2020

    Either ADT + Docetaxel and ADT + Abiraterone is valid in this case

  • GANDA Oumarou Sanda

    Feb 21, 2020

    ADT+ abiraterone
Fractioned  radiotherapy if bone pain

  • Hisashi Matsushima

    Feb 22, 2020

    There is no obvious organ metastasis in this case.
Standard ADT+ abiraterone + predonisone should be preferred.

  • Radoslav Mangaldzhiev

    Feb 22, 2020

     If he was fit I would recommend ADT + DOC in first choice due to high volume disease.

  • Judy Hiemenga

    Feb 22, 2020

    And please don’t omit an early consult in Cancer Genetics.

  • Huan Wang

    Feb 23, 2020

    ADT+DOC or ADT+Abiraterone is a reasonable treatment choice based on CHARTTED and LATITUDE study. The patient is young with high volume disease, genetic testing should be recommend strongly.

  • Samba Thiapato  Faye

    Feb 24, 2020

    In our daily practice, we do ADT + Docetaxel if the patient is fit... If he isn't it, we use ADT only + Prednisone.

  • Ismail Abdelhafeez

    Feb 27, 2020

    ADT + DOC , pending on response post chemo, may advise Lutitium 177 in a clinical trial!
  • Comment deleted by User.

  • Ofobuike Okani

    Apr 02, 2020

    I would start with  ADT+DOC + bisphosphonate if PS is <2 and GFR is >60. If PS is >2, would start with Abiraterone+Pred and add a bisphosphonate if GFR>60.

  • Apr 23, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated